RLYP Key Stats
- Nasdaq stocks posting largest percentage decreases Yahoo 03/05 18:03 ET
- Relypsa to Present at Two Upcoming Investor Conferences in March GlobeNewswire 02/26 09:00 ET
- Why Cadence Pharmaceuticals, Relypsa, and Hansen Medical Are Today's 3 Best Stocks Yahoo 02/11 17:16 ET
- Relypsa Completes Enrollment of Phase 1 Onset-of-Action Study for Patiromer GlobeNewswire 02/04 16:00 ET
- Relypsa to Present at BIO CEO Conference February 10 GlobeNewswire 02/03 09:00 ET
- RELYPSA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Yahoo 01/13 09:29 ET
- Relypsa Provides Corporate Update GlobeNewswire 01/13 09:00 ET
- RELYPSA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits 12/23 16:13 ET
- Why I Think Relypsa Is Overvalued By $400M 12/19 03:44 ET
- The Best- And Worst-Performing Biotech Stocks, Dec. 6 to Dec. 13 Yahoo 12/14 08:29 ET
RLYP Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Relypsa is up N/A over the last year vs S&P 500 Total Return up 24.37%, Acorda Therapeutics up 24.36%, and PDL BioPharma up 27.26%.
Balance Sheet View Statement
Pro Ratings for RLYP
Pro Report PDF for RLYP
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download RLYP Pro Report PDF
Pro Strategies Featuring RLYP
Did Relypsa make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: California
- Incorporation Country: United States
- Incorporation State/Province: Delaware
Relypsa Inc is engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States.